HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Three-year clinical follow-up of an unselected patient population treated with the genous endothelial progenitor cell capturing stent.

AbstractBACKGROUND:
We assessed the 3-year clinical outcome in our single-center cohort of mainly unselected patients treated with the endothelial progenitor cell capturing stent (ECS). The ECS is coated with CD34+ antibodies specifically targeting the circulating endothelial progenitor cells population to accelerate endothelialization that in turn may prevent the occurrence of in-stent restenosis and stent thrombosis (ST).
METHODS:
All patients in our study had coronary artery lesions that were treated with an ECS. The majority of patients had complex lesions with an estimated high risk of restenosis.
RESULTS:
A total of 405 patients were enrolled. The primary end-point of target lesion failure (TLF) was defined as the composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). At 3 years, TLF was 18.3% and TLR was 14.2%. Early ST occurred in 2 patients. No cases of late and very late definite ST were reported.
CONCLUSIONS:
This single-center study demonstrates the safety at 3 years of the ECS in an unselected patient population, including a fair number of patients with complex lesions, reflecting daily practice. Our data compare well with drug-eluting stent and bare metal stent registries enrolling unselected patient populations. Importantly, in our analysis, no cases of late or very late definite ST were reported.
AuthorsMargo Klomp, Marcel A M Beijk, Peter Damman, Pier Woudstra, Karel T Koch, Jan G P Tijssen, Robbert J de Winter
JournalJournal of interventional cardiology (J Interv Cardiol) Vol. 24 Issue 5 Pg. 442-9 (Oct 2011) ISSN: 1540-8183 [Electronic] United States
PMID22004602 (Publication Type: Journal Article)
Copyright©2011, Wiley Periodicals, Inc.
Chemical References
  • Antigens, CD34
Topics
  • Antigens, CD34 (immunology)
  • Coronary Angiography
  • Coronary Restenosis (prevention & control)
  • Endothelial Cells (cytology)
  • Endothelium, Vascular (cytology)
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk Factors
  • Stem Cells (cytology)
  • Stents
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: